Kailera Therapeutics
KLRA
10.53
-0.30
-2.77%
Kailera Therapeutics
US · KLRA
#3073 by market cap
Listed 2026
10.53
-0.30
-2.77%
Live - 5344 symbols - heartbeat 100s ago
· 2026-10-08 07:08
Pre-market
10.68
+1.42%
After-hours
10.53
0.00%
- Market cap
- 1.37B
- P/E (TTM)i
- -4.67
- P/Bi
- 1.22
- EPSi
- -0.01
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on KLRA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | 49.23M |
| Research & development | -- | 109.11M |
| Operating profit | -- | -158.34M |
| Pretax profit | -- | -148.96M |
| Tax | -- | -- |
| Net profit | -- | -148.96M |
| Basic EPS | -- | -1 |
| Diluted EPS | -- | -1.26 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 10.33M | 11.13M | 13.79M | 20.31M |
| Research & development | 10.13M | 19.52M | 70.87M | 101.06M |
| Operating profit | -20.46M | -30.65M | -84.66M | -121.37M |
| Pretax profit | -17.98M | -28.95M | -78.87M | -111.31M |
| Tax | -- | -- | -- | -- |
| Net profit | -17.98M | -28.95M | -78.87M | -111.31M |
| Basic EPS | 0 | 0 | -1 | -1 |
| Diluted EPS | -0.15 | -0.25 | -0.67 | -1.09 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 177.61M | 557.54M |
| Cash & ST investments | 175.18M | 546.06M |
| Inventory | -- | -- |
| Total assets | 178.45M | 692.29M |
| Total current liabilities | 6.91M | 46.41M |
| Short-term debt | 509.00K | 1.04M |
| Long-term debt | -- | -- |
| Total liabilities | 397,217,000.00 | 1,048,752,000.00 |
| Total equity | -218.77M | -356.46M |
| Retained earnings | -219.71M | -368.67M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 530.32M | 929.17M |
| Cash & ST investments | -- | -- | 519.17M | 916.74M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 624.76M | 1.21B |
| Total current liabilities | -- | -- | 54.84M | 83.65M |
| Short-term debt | -- | -- | 1.03M | 1.05M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 1,056,844,000.00 | 92,952,000.00 |
| Total equity | -- | -- | -432.09M | 1.12B |
| Retained earnings | -- | -- | -447.53M | -558.84M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -- | -120.21M |
| Depreciation & amortization | -- | 310.00K |
| Free cash flow | -- | -122.30M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | -- | 161.03M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -18.20M | -26.23M | -68.31M | -77.53M |
| Depreciation & amortization | 63.00K | 62.00K | 101.00K | 101.00K |
| Free cash flow | -18.20M | -26.23M | -68.31M | -77.53M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 102.54M | 102.13M | 112.59M | 131.06M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -- | -34.21 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 25.70 | 12.01 |
| Quick ratioi | 25.35 | 11.83 |
| Debt / assetsi | 0.29 | 1.55 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -26.12 |
| ROA %i | -- | -- | -33.59 | -24.12 |
| ROIC %i | -- | -- | -- | -27.92 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 9.67 | 11.11 |
| Quick ratioi | -- | -- | 9.53 | 11.03 |
| Debt / assetsi | -- | -- | 1.68 | 0.84 |
| LT debt / equityi | -- | -- | -- | 0.82 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-08 07:08:07 · For reference only, not investment advice and not tailored to your situation.